Bluejay Diagnostics, Inc. (BJDX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029420901ex10-1.htm BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO. 1 THERETO Exhibit 10.1 BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO.1 THERETO Section 1. Establishment and Purpose. 1.1 The Board of Directors (the “Boa
How this was made
The 30-second read
Why it matters
Equity-plan amendments can influence future compensation structure and potential share issuance/dilution, but the provided excerpt is largely definitional/administrative and does not quantify immediate economic impact.
Market read
This is primarily governance/compensation-plan documentation; actionable trading impact depends on whether the full 8-K specifies material changes to share pool limits or specific officer/director actions.
What to watch
Traders should check the complete 8-K exhibits for (i) actual officer/director appointments/departures, (ii) any new share pool limits, and (iii) grant/SAR/option terms that could change near-term dilution expectations.
Background
The filing is an SEC 8-K (Item 5.02/5.07) that includes an exhibit describing the Bluejay Diagnostics 2021 Stock Plan as amended, with stockholder approval on June 9, 2026.
Ticker impact
Bluejay Diagnostics amended its 2021 Stock Plan (approved by stockholders June 9, 2026) via an 8-K covering director/officer and compensatory arrangements.
Near-term impact likely limited unless the filing also specifies material grant volumes or dilution mechanics (not provided in the excerpt).
The excerpt shows plan amendment approval and administrative/definition language, but does not disclose specific grant sizes, exercise terms, or immediate financial impact.
Market effects
Minimal—this is company-specific equity-compensation governance rather than a sector-wide regulatory or clinical catalyst.
None indicated.
None indicated.
Counterpoint
If the full 8-K includes specific officer/director changes or unusually large equity awards, the dilution overhang could be more meaningful than the plan text alone suggests.
Key entities
- issuerBluejay Diagnostics, Inc.
Company amending its 2021 Stock Plan and reporting director/officer and compensatory arrangements via SEC 8-K.
- equity_compensation_plan2021 Stock Plan (Amendment No. 1)
Stockholder-approved plan amendment effective after June 9, 2026 approval.
